PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma

被引:8
|
作者
Garige, Mamatha [1 ]
Ghosh, Susmita [1 ]
Norris, Alexis [2 ]
Li, Guangyuan [1 ]
Poncet, Sarah [1 ]
Chou, Chao-Kai [3 ]
Wu, Wells W. [3 ]
Shen, Rong-Fong [3 ]
Sourbier, Carole [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biotechnol Review & Res 1, Off Biotechnol Prod,Off Pharmaceut Qual, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Vet Med, Div Anim Bioengn & Cellular Therapies, Off New Anim Drug Evaluat, Rockville, MD USA
[3] US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Drug Adm, Silver Spring, MD USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
PD-L1 (B7-H1; CD274); clear cell renal cell carcinoma (ccRCC); interferon gamma; metabolism; tryptophan; kynurenine; glycolysis; INDOLEAMINE 2,3-DIOXYGENASE; SUPPRESSOR-CELLS; INTERFERON-GAMMA; T-CELLS; CANCER; MICROENVIRONMENT; INFLAMMATION; EXPRESSION; LINDAU; ACID;
D O I
10.3389/fonc.2022.858379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune checkpoint programmed death-ligand 1 (PD-L1) is expressed on the cell surface of tumor cells and is key for maintaining an immunosuppressive microenvironment through its interaction with the programmed death 1 (PD-1). Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic cancer characterized by an aberrant aerobic glycolytic metabolism and is known to overexpress PD-L1. Multiple immunotherapies have been approved for the treatment of ccRCC, including cytokines and immune checkpoint inhibitors. Recently the intrinsic role of PD-L1 and interferon gamma (IFN gamma) signaling have been studied in several types of tumor cells, yet it remains unclear how they affect the metabolism and signaling pathways of ccRCC. Using metabolomics, metabolic assays and RNAseq, we showed that IFN gamma enhanced aerobic glycolysis and tryptophan metabolism in ccRCC cells in vitro and induced the transcriptional expression of signaling pathways related to inflammation, cell proliferation and cellular energetics. These metabolic and transcriptional effects were partially reversed following transient PD-L1 silencing. Aerobic glycolysis, as well as signaling pathways related to inflammation, were not induced by IFN gamma when PD-L1 was silenced, however, tryptophan metabolism and activation of Jak2 and STAT1 were maintained. Our data demonstrate that PD-L1 expression is required to mediate some of IFN gamma's effect in ccRCC cells and highlight the importance of PD-L1 signaling in regulating the metabolism of ccRCC cells in response to inflammatory signals.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
    Larrinaga, Gorka
    Solano-Iturri, Jon Danel
    Errarte, Peio
    Unda, Miguel
    Loizaga-Iriarte, Ana
    Perez-Fernandez, Amparo
    Echevarria, Enrique
    Asumendi, Aintzane
    Manini, Claudia
    Angulo, Javier C.
    Lopez, Jose I.
    CANCERS, 2021, 13 (04) : 1 - 17
  • [2] Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma
    Kong, Su-Kang
    Kim, Byung Soo
    Lim, Hyangsoon
    Kim, Hyun Ji
    Kim, Young-Sik
    LABORATORY INVESTIGATION, 2022, 102 (04) : 352 - 362
  • [3] Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
    Spirina, Liudmila
    Yurmazov, Zahar
    Usynin, Evgeny
    Kondakova, Irina
    Ladutko, Ekaterine
    Choynzonov, Evgeny
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2021, 43 (02) : 1072 - 1080
  • [4] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [5] A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
    Nunes-Xavier, Caroline E.
    Angulo, Javier C.
    Pulido, Rafael
    Lopez, Jose I.
    CURRENT UROLOGY REPORTS, 2019, 20 (01)
  • [6] Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma
    Lin, Hansen
    Fu, Liangmin
    Li, Pengju
    Zhu, Jiangquan
    Xu, Quanhui
    Wang, Yinghan
    Mumin, Mukhtar Adan
    Zhou, Xinwei
    Chen, Yuhang
    Shu, Guannan
    Yao, Gaosheng
    Chen, Minyu
    Lu, Jun
    Zhang, Lizhen
    Liu, YuJun
    Zhao, Yiqi
    Bao, Jiahao
    Chen, Wei
    Luo, Junhang
    Li, Xiaofei
    Chen, Zhenhua
    Cao, Jiazheng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [7] PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
    Jilaveanu, L. B.
    Shuch, B.
    Zito, C. R.
    Parisi, F.
    Barr, M.
    Kluger, Y.
    Chen, L.
    Kluger, H. M.
    JOURNAL OF CANCER, 2014, 5 (03): : 166 - 172
  • [8] PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives
    Zhu, Zhaoyang
    Jin, Yigang
    Zhou, Jing
    Chen, Fei
    Chen, Minjie
    Gao, Zhaofeng
    Hu, Lingyu
    Xuan, Jinyan
    Li, Xiaoping
    Song, Zhengwei
    Guo, Xiao
    MOLECULAR CANCER, 2024, 23 (01)
  • [9] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    Abbas, M.
    Steffens, S.
    Bellut, M.
    Eggers, H.
    Grosshennig, A.
    Becker, J. U.
    Wegener, G.
    Schrader, A. J.
    Gruenwald, V.
    Ivanyi, P.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [10] Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Kurose, Hirofumi
    Chikui, Katsuaki
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Kawahara, Akihiko
    Yano, Hirohisa
    Igawa, Tsukasa
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (11) : 499.e9 - 499.e16